A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant.
Erin M EulianoBrett H PogostinAnushka AgrawalMarina H YuTsvetelina H BaryakovaTyler P GrafJeffrey D HartgerinkKevin J McHughPublished in: bioRxiv : the preprint server for biology (2024)
Activation of toll-like receptors (TLRs) stimulates a signaling cascade to induce an immune response. A TLR7 agonist was conjugated to an injectable peptide hydrogel, which was then used to deliver a model vaccine antigen. This platform produced antibody titers similar to the gold standard adjuvant alum and demonstrated an improved balance between Th1- and Th2-mediated immunity over alum.